P Wantzin

Copenhagen University Hospital Hvidovre, Hvidovre, Capital Region, Denmark

Are you P Wantzin?

Claim your profile

Publications (20)65.26 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Following a survey among all Danish haemophiliac patients 49 HIV-negative patients with chronic hepatitis C were offered enrollment in a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Dose modifications and treatment discontinuation were based upon changes in transaminase levels. Forty-seven patients enrolled received 3 MU of alpha interferon thrice weekly (TIW) for 3 months. Twenty-six nonresponders had their dose increased to 6 MU TIW for an additional 3 months, while 21 responding patients continued on 3 MU TIW. At 6 months, 25 patients with a complete or a partial biochemical response were randomly allocated to either a fixed dose regimen (13 patients) (3 or 6 MU thrice weekly) or an individualized dose regimen (12 patients) tapering interferon dose from 3 or 6 MU by one-third every 2 months if transaminases were persistently normal. The remaining 22 biochemical nonresponders were followed for an additional 6 months without further treatment. After 12 months of treatment, 18 patients (38%) had a virological response, irrespective of regimen, and seven patients (16%) had a sustained virological and biochemical response after 6 months of follow up. Overall, the individualized treatment regimen did not seem to offer any advantage over the fixed dose regimen. The response to alpha interferon treatment in Danish haemophiliac patients with chronic hepatitis C immediately after treatment is comparable to that obtained in previous studies among nonhaemophiliacs. However, a sustained virological and biochemical response was seen in only 16% of treatment patients.
    Haemophilia 02/1998; 4(1):25-32. · 3.17 Impact Factor
  • A M Worm, H Westh, B B Kvinesdal, P S Wantzin
    Acta Dermato Venereologica 06/1996; 76(3):249-50. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Health care workers are at risk of acquiring blood-borne infections. To assess the risk of exposure to hepatitis B or C in the case of occupational blood exposure, we determined the seroprevalence of these infections in 466 patients admitted to a Copenhagen university hospital. Serological markers for hepatitis B or C were detected in 56 patients (12.0%). The seroprevalence of HBsAg and anti-HCV was 0.9% and 1.5% respectively. HCV RNA, indicating ongoing hepatitis C, was found in five of seven anti-HCV-positive patients by polymerase chain reaction. The serological findings had not previously been diagnosed in 4 of 10 potentially infectious patients and only 6 of 10 patients belonged to high-risk groups. In conclusion, health care workers should be aware of the potential the occupational risk of hepatitis B and C even in a low-prevalence country like Denmark. Management of health care workers after blood exposure should include serological testing for both hepatitis B and C. Strict adherence to universal precautions is recommended and vaccination against hepatitis B should be encouraged.
    Scandinavian Journal of Infectious Diseases 02/1995; 27(5):445-8. · 1.71 Impact Factor
  • Vox Sanguinis 02/1995; 68(1):63-4. · 2.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Results of serologic tests were correlated with hepatitis C virus (HCV) viremia, determined by a cDNA polymerase chain reaction assay to detect HCV RNA, in 340 Danish dialysis patients; of these, 28 (8.2%) were positive for antibodies to HCV (anti-HCV) with second-generation ELI-SAs. HCV RNA was found in sera from 27 of these 28 anti-HCV-positive patients. However, 8 dialysis patients had detectable levels of HCV RNA but were anti-HCV-negative with second-generation ELISAs. Among the 35 HCV-infected dialysis patients 16 were positive, 7 indeterminate, and 12 negative with the second-generation RIBA. More than 60% of patients with evidence of ongoing liver disease had HCV infection. Thus, current commercially available antibody tests did not accurately reflect the HCV status in dialysis patients. A relatively high prevalence (> 10%) of HCV RNA, closely associated with liver disease, was found among dialysis patients in a low-prevalence area of the world.
    The Journal of Infectious Diseases 12/1993; 168(6):1343-8. · 5.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies to hepatitis C virus (anti-HCV) were determined in an unselected group of 340 patients with chronic renal failure treated with maintenance dialysis. A second generation hepatitis C virus (HCV) enzyme-linked immunosorbent assay (ELISA) was used and confirmation made by a second generation recombinant immunoblot assay (RIBA). Sixteen patients (4.7%) were anti-HCV positive and 8 (2.4%) were anti-HCV indeterminate. All anti-HCV positive and anti-HCV indeterminate patients had received blood transfusions. No statistically significant differences were found between anti-HCV positive and indeterminate patients considering blood transfusions, dialysis and liver disease. The combined group of anti-HCV positive and indeterminate patients had had more blood transfusions (P < 0.005) and had been on dialysis for a longer period (P < 0.01) compared with anti-HCV negative patients. Further, significant correlation with elevation of transaminases and anti-HCV was observed (P < 0.001). Thirty patients (8.8%) had elevated transaminase levels and 13 (43%) of these were anti-HCV positive or indeterminate. In conclusion, HCV infection accounts for a substantial proportion of liver disease in dialysis patients, probably most often transmitted by blood transfusions but other routes of transmission could not be excluded.
    Kidney International 06/1993; 43(6):1353-6. · 8.52 Impact Factor
  • Infection 01/1993; 21(2):115-117. · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to evaluate the role of sexual transmission and parenteral transmission of hepatitis C virus (HCV) in homosexual men and intravenous drug users (IVDU) serum samples from 147 homosexual men and 126 IVDU were tested for anti-HCV. Anti-HCV was found in two (1.4%) of the homosexual men and in 123 (98%) of IVDU. The presence of anti-HCV could not be correlated to the presence of HBV markers or HIV-antibodies. HCV is widespread among Danish IVDU. Risk of sexual transmission seems low even though sexual contact is a much more prevalent risk factor than needle sharing.
    Infection 01/1993; 21(2):115-7. · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Seventy-six of 77 consecutive patients with hepatitis B surface antigen (HBsAg)-positive acute hepatitis were reevaluated using anti-hepatitis C virus (HCV), anti-hepatitis D virus (HDV), and IgM anti-hepatitis B core (HBc) testing. Anti-HCV and/or anti-HDV was found in 32 patients (42%). The presence of these markers was significantly associated with intravenous drug abuse (p less than 10(-6). Sixty-nine patients were IgM anti-HBc-positive, of whom two (3%) (95% confidence limits, 1-12%) became chronic HBsAg carriers with histologically verified chronic liver disease; both were anti-HCV and anti-HDV-negative. Among the remaining 67 IgM anti-HBc-positive patients 8 had HBV and HDV co-infection, 3 had HBV and HCV co-infection, and 1 had HBV, HCV, and HDV co-infection. Twenty-two had evidence of preceding or past HCV infection; two developed chronic active hepatitis in spite of HBsAg clearance. Seven patients with IgM anti-HBc negative. One was a chronic HBsAg carrier with HDV superinfection. One had subclinical acute HBV infection and became a chronic HBsAg carrier. In a further two patients reactivation of replication in a chronic HBV infection could not be disregarded. Three patients could not be classified; all had acute recent onset of symptoms, cleared HBsAg within 6 months, but lacked IgM anti-HBc. It is concluded that HCV and HDV superinfections in HBV carriers mimicking acute HBV infection with chronic evolution are rarely encountered in the present population in spite of high frequency of both HCV and HDV markers.
    Scandinavian Journal of Gastroenterology 04/1991; 26(3):275-80. · 2.16 Impact Factor
  • AIDS 11/1990; 4(10):1039-40. · 6.41 Impact Factor
  • P S Wantzin, K Krogsgaard, E Dickmeiss
    [Show abstract] [Hide abstract]
    ABSTRACT: In Denmark only 1-3 cases of transfusion-associated hepatitis NANB (TAH-NANB) are registered annually or about 1 case per 100,000 units transfused. Thus, the prevalence of blood donors with hepatitis NANB infection is estimated to be very low and measures to prevent TAH-NANB such as surrogate testing have not been considered to be worth while. The incidence of TAH-NANB, however, may be underestimated if cases are overlooked or not identified as transfusion-associated or if registration fails. The appearance of the anti-HCV test (Ortho) has clearly provided a more sensitive and specific tool for identifying blood donors, who may transmit hepatitis NANB. In the present study, we have determined the prevalence of anti-HCV in random Danish blood donors from 1989 (fresh serum samples) and 1982 (frozen serum samples). All donors were tested for ALT and anti-HBc. A prevalence of 0.3% anti-HCV positive blood donors was found in 1989 (2/600) as well as in 1982 (2/595). Thus, no change in the prevalence of HCV infected donors seems to have occurred in Denmark during these years. The anti-HCV prevalence of 0.3% in random blood donors is low but not negligible, and if the majority of the reactive donors identified are true positives, the epidemiologic pressure as to HCV infection probably equalizes the pressure as to HBV infection (0.1-0.2%) in people attending our blood banks to become donors. In a group of donors positive for surrogate markers (ALT greater than 40 U/l and/or anti-HBc) we found only 0.9% (2/225) anti-HCV positives.(ABSTRACT TRUNCATED AT 250 WORDS)
    Ugeskrift for laeger 10/1990; 152(39):2846-8.
  • K Krogsgaard, P Wantzin
    Ugeskrift for laeger 10/1990; 152(39):2833-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the prevalence, incidence, and persistence of positivity for antibodies to hepatitis C virus (anti-HCV) and the potential for sexual transmission of the virus. A cohort analysis covering 1981-9 comparing estimated cumulative incidences of and seroconversion rates for anti-HCV with those of hepatitis B core antibody (anti-HBc) and antibodies to the human immunodeficiency virus (anti-HIV). Copenhagen and Aarhus, Denmark. 259 Male members of a Danish homosexual organisation. Correlations of prevalence and incidence with a wide range of sexual lifestyle variables. Only four (1.6%) subjects were positive for anti-HCV in 1981. The estimated cumulative incidence of positivity for anti-HCV was 4.1% in 1984 (seroconversion rate during 1981-4 (2.5%)) and remained at 4.1% in 1989 (seroconversion rate nil during 1984-9). In contrast, positivity for anti-HBC rose from 44.0% in 1981 to 52.7% in 1984 (seroconversion rate 15.5%) and 58.8% in 1989 (seroconversion rate 12.9%), and that for anti-HIV rose from 8.8% to 24.0% (seroconversion rate 16.7%) and 30.1% (seroconversion rate 8.0%) respectively. Three anti-HCV positive patients seroreverted three to five years later. None of the anti-HCV positive subjects had had a transfusion and only one gave a past history of intravenous drug use. Variables in sexual lifestyle correlated with the presence of anti-HBc but not with that of anti-HCV. In contrast with hepatitis B virus and HIV, sexual transmission of hepatitis C virus seems to be a rare event. Furthermore, antibodies to the virus may become undetectable after several years.
    BMJ Clinical Research 08/1990; 301(6745):210-2. · 14.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 24 consecutive patients (14 females; median age 36, range 18-77) with liver biopsy proven acute non-A, non-B hepatitis (NANBH) were assayed for antibodies to hepatitis C virus (HCV). 14 (58%) were positive initially or during follow-up. Three patients were positive within 4 weeks following onset of symptoms and 7 patients in a serum sample obtained 4-8 weeks after clinical onset. Seroconversion was documented in 7/8 patients in paired sera from the acute phase of the disease. Anti-HCV was detected in 6% and 13% of control patients with acute hepatitis A and toxic hepatitis. NANBH in 6/14 patients (43%) with anti-HCV progressed to chronic liver disease (CLD). In contrast none of the anti-HCV negative patients developed CLD (p = 0.02). In addition, 2 anti-HCV positive patients developed fulminant and fatal hepatitis. The predominant route of HCV transmission was intravenous drug abuse. It is concluded that hepatitis may be ascribed to HCV infection in more than half of patients with community aquired NANBH, that seroconversion occurs in the majority within 8 weeks following onset of symptoms and that seropositive individuals often progress to CLD.
    Scandinavian Journal of Infectious Diseases 02/1990; 22(4):399-402. · 1.71 Impact Factor
  • Ugeskrift for laeger 02/1987; 149(2):84-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Owing to the low incidence of hepatitis B in Denmark, screening of blood donors for HBsAg has mostly been done by immunoelectroosmophoresis (IEOP). The purpose of the present study was to carry out a cost-effectiveness analysis prior to the introduction of a third-generation test for HBsAg in Danish blood donors. The analysis was performed on data from a subsequent screening of 48 750 blood units by radioimmunoassay (RIA) 3 weeks after donation. The RIA-pos., IEOP-neg. blood donors identified in the study were evaluated by a follow-up examination, and the recipients of RIA-pos., IEOP-neg. blood units were monitored for up to 9 months as to the development of acute hepatitis B. The study shows that the estimated cost for each prevented case of transfusion-associated hepatitis B in Denmark is US$ 1100 when screening donors not previously tested by a third-generation technique, and US$ 240 000 when screening donors tested before by this technique.
    Liver International 07/1986; 6(3):173-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The presence of hepatitis B virus (HBV) DNA was investigated in 26 hepatitis B surface antigen-positive blood donors. Three donors (12%) were concordantly positive for HBV DNA and hepatitis B e antigen (HBeAg) and had IgM antibody to hepatitis B core antigen (anti-HBc). Two donors (8%) had HBV DNA without HBeAg; both were positive for antibody to HBeAg and lacked IgM anti-HBc. Twenty-one HBV DNA-negative donors had antibody to HBeAg, and all were negative for HBeAg and IgM anti-HBc. Blood units from 16 donors were transfused. A sufficient serological and clinical follow-up was available for 10 HBV-susceptible recipients. Three recipients of HBV DNA-positive blood units were infected irrespective of HBeAg status or presence of IgM anti-HBc. Six (86%) of seven recipients of HBV DNA-negative blood units developed HBV infection. Thus all hepatitis B surface antigen-positive blood donors should still be considered infectious irrespective of status with regard to HBeAg, HBV DNA, and IgM anti-HBc.
    The Journal of Infectious Diseases 03/1986; 153(2):298-303. · 5.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The profit to be gained by testing Danish blood donors for hepatitis B surface antigen (HBsAg) with a third generation technique instead of the currently used immunoelectrophoresis was investigated by additional screening of 48 750 blood units by radioimmunoassay three weeks after donation. Twenty nine units were positive for HBsAg on radioimmunoassay (0.059%). Only six of these were found by immunoelectrophoresis (0.012%). Most of the 23 donors positive on radioimmunoassay and negative on immunoelectrophoresis were healthy carriers of HBsAg (20) or had asymptomatic chronic liver disease (two). One donor had acute hepatitis B. Fifteen of the 23 blood units were transfused. The 15 recipients were monitored biochemically and serologically for up to nine months. One recipient developed fulminant hepatitis B, three developed acute hepatitis B, and one became a healthy carrier of HBsAg. All these patients had received blood from healthy carriers of HBsAg. Two recipients were immunised against HBsAg, and in one patient no seroconversion was observed. The remaining recipients died soon after transfusion or were protected by antibodies to HBsAg that had been present before the transfusion. Testing of Danish blood donors using a third generation technique identified a substantial number of donors positive for HBsAg overlooked by immunoelectrophoresis. Most of these donors were healthy carriers of HBsAg. Blood taken from such carriers is highly infectious when transfused, probably because of the large amount of material transmitted.
    British medical journal (Clinical research ed.) 10/1985; 291(6498):780-2.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Direct immunofluorescence studies were performed on isolated liver cells in order to detect surface localisation of IgG in acute and chronic hepatitis and primary biliary cirrhosis. Membrane-bound IgG was demonstrated in nine patients. Six of eight patients with primary biliary cirrhosis showed granular fluorescence on their liver cell surfaces suggesting that an antibody or immune complex-mediated cytotoxicity might be involved in the pathogenesis of this disease.
    Journal of Clinical Pathology 11/1981; 34(10):1076-9. · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thirty-six persons found to be healthy HBsAg carriers by routine donor screening from 1970 to 1973 were offered a follow-up examination in 1978. A total of 21 out of the 34 still living carriers were reexamined clinically, serologically, and biochemically. Seventeen of the 20 still HBsAg-positive carriers had anti-HBe, and 2 were HBeAg-positive. Liver biopsy in these two carriers showed chronic persistent hepatitis. No biochemical abnormalities were found in any but one who was HBeAg-positive and one who was negative for both HBeAg and anti-HBe. Anti-HBc titers varied between 1:3,600 and 1:83,000. Circulating immune complexes were demonstrated in 30% of the healthy HBsAg carriers. On the basis of 5-8 years' follow-up it is concluded that the healthy HBsAg carrier state is a benign condition that has not affected the carrier's quality of life. Progression to a severe, chronic liver disease was not observed in any of the healthy carriers. The importance and nature of circulating immune complexes in healthy HBsAg carriers was unknown and need further investigation.
    Scandinavian Journal of Gastroenterology 02/1981; 16(8):1077-81. · 2.16 Impact Factor

Publication Stats

320 Citations
65.26 Total Impact Points


  • 1981–1998
    • Copenhagen University Hospital Hvidovre
      • Department of Infectious Diseases
      Hvidovre, Capital Region, Denmark
  • 1993
    • Bispebjerg Hospital, Copenhagen University
      • Department of Dermatology
      København, Capital Region, Denmark
  • 1990
    • Rigshospitalet
      København, Capital Region, Denmark